On October 17, U.S. startup Nucleus RadioPharma announced the completion of a $56 million Series A financing round.Aimed at manufacturing radioactive isotope cancer treatment drugs。
This round of financing came from venture capitalists and academic institutions,Including Eclipse VC, GE HealthCare, Mayo Clinic, and the University of Missouri.This round of funding willFor the expansion of new production bases, supply chain facilities, and the development and manufacturing of more radiopharmaceuticals。After this round of financing, Nucleus has raised a total of $62 million.Notably, Nucleus was co-founded by Mayo Clinic and Eclipse VC in 2022, with the founder beingCharles Conroy, whose headquarters is located inRochester, Minnesota, and close to the Mayo Clinic.
Radioactive drugs deliver radioactive substances directly to cancer cells, killing them while preserving healthy tissue.Nucleus is the world's largest radiopharmaceuticals treatment center., it is committed to becoming the preferred partner for the development and production of radiopharmaceuticals.In recent years, scientists, investors, and pharmaceutical companies have been betting on targeted drugs in the hope of providing more effective treatments for certain tumors, such as prostate and intestinal cancers.The approval and commercial success of Novartis' treatments Pluvicto and Lutathera have validated this bet, spurring investments in new research by companies such as RayzeBio, Aktis Oncology, and Mariana Oncology.At the beginning of this month, Eli Lilly also acquired Point Biopharma for $1.4 billion. Point Biopharma has radioligand therapies in clinical and preclinical stages for the treatment of cancer.But it cannot be ignored that the main obstacles to drug development still exist.Radioactive drugs are difficult to produce on a large scale, partly due to the limited supply of radioactive materials and restrictions on transportation methods.Radiopharmaceuticals must be produced and delivered rapidly to ensure the efficacy of their radioactive components. The radioactive isotopes within the drugs may have only a few days or hours before they degrade.To overcome these challenges, Nucleus plans to open "multiple large regional sites" across the United States to meet the demand for radiopharmaceutical production.Nucleus claims that the scale of this plan will make it unique in the industry."Our goal is to help companies identify and develop molecules in the early stages, and then ensure their commercial delivery," said founder Conroy."As truly targeted therapies, these drugs have not only proven to be highly effective but also maintained excellent safety."。https://www.biopharmadive.com/news/nucleus-radiopharmaceutical-biotech-startup-manufacturing/696714/
